AFM
KZR

Anson Funds Management’s Kezar Life Sciences KZR Stock Holding History

Anson Funds Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-61,125
Closed -$579K – 186
2023
Q4 		$579K Buy
+61,125
New +$537K 0.07% 123

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Anson Funds Management's KZR Position: Q1 2024 in Review

Anson Funds Management sold out of Kezar Life Sciences (KZR) in Q1 2024, closing a stake of 61,125 shares — an estimated $579K sold.

Anson Funds Management first reported a position in KZR in Q4 2023 and held it in 1 quarter. The position peaked at $579K in Q4 2023. 85 funds tracked by Wall St. Rank hold KZR as of Q1 2024.

  • Anson Funds Management reported no remaining Kezar Life Sciences position as of Q1 2024 after selling out during the quarter.
  • Anson Funds Management sold 61,125 Kezar Life Sciences shares in Q1 2024, an estimated $579K.
  • Anson Funds Management first reported a position in Kezar Life Sciences in Q4 2023 and held it in 1 quarter.
  • Anson Funds Management's Kezar Life Sciences position peaked at $579K in Q4 2023.
  • 85 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2024.

Based on Anson Funds Management's 13F filing for Q1 2024, filed 14 May 2024.